Graysky, a third-party client for X rival Bluesky, gets Trending Topics and a ‘Pro’ subscription

December 13, 2023

Graysky, one of the first third-party apps for the Twitter/X competitor Bluesky, is launching a subscription service with its latest release, as a means of generating revenue for its app by offering paid access to features that Bluesky itself doesn’t yet support. In the initial release, users will be able to personalize the app with […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Receive the gift of growth at TechCrunch Early Stage 2024

December 13, 2023

Gift giving. It’s top of mind this time of year, and we’re here to suggest two ways you can spread joy this holiday season. First, never — and we mean never — give the “gift” of fruit cake. Second, give your startup dream the gift of growth. Treat yourself and your business with a pass […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Circuit City, angling for a comeback of sorts, hopes to raise $25M

December 13, 2023

At the risk of dating myself, I’m old enough to remember the days when Best Buy had a formidable rival in superstore chains: Circuit City. A cross between an appliance store (at least until it stopped selling appliances) and all-around electronics retailers, Circuit City was the place to be for nerdy, tech-obsessed kids like myself […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Apple will no longer give police users’ push notification data without a warrant

December 13, 2023

Apple said it will no longer give over records of users’ push notifications to law enforcement unless the company receives a valid judge’s order. In its law enforcement guidelines updated this week, Apple said law enforcement and government agencies can now obtain push notification records with a court order or a search warrant, both of […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Vertex will pay tens of millions to license a controversial CRISPR patent

December 13, 2023
Vertex Pharmaceuticals has agreed to buy rights to use a dominant CRISPR patent owned by the Broad Institute of Harvard and MIT, avoiding a potential lawsuit over its new gene-editing treatment for sickle-cell disease. The agreement allows Vertex to start selling its treatment, approved last Friday, without fear of patent infringement claims. The one-time treatment…